Skip to content
Screener

IDEAYA Biosciences, Inc. IDYA Operating Lease Liabilities

Operating Lease Liabilities at other companies

Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$13.72M-10.1%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$29.96M-12.2%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
$245.09M—
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Erasca, Inc. logo
Erasca, Inc.ERAS
$40.7M-11.6%
Nuvation Bio logo
Nuvation BioNUVB
$1.91M-43.8%

Other financials

Income statement

See full
Revenue$6.6M—
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0×0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemMarch 31, 2026December 31, 2025
Accrued liabilities43,74540,892
Operating lease liabilities, current350339
Total current liabilities64,83158,815
Long-term operating lease liabilities28,25027,575
Total liabilities93,08186,390
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025——

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s operating lease liabilities?
IDEAYA Biosciences, Inc. (IDYA) reported operating lease liabilities of $28.25M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s operating lease liabilities changed year-over-year?
IDEAYA Biosciences, Inc.'s operating lease liabilities increased by 10.1% year-over-year, from $25.66M to $28.25M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s operating lease liabilities?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s operating lease liabilities has grown at a 39.7% compound annual growth rate (CAGR), from $5.18M to $27.58M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about IDEAYA Biosciences, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude